If approved, we are ready to offer a convenient, once-daily pill that can be scaled globally, removing barriers and redefining how obesity is treated around the world, Kenneth Custer, PhD, Lilly executive vice president and president of Lilly Cardiometabolic Health, said in an August 26 statement
As such, the answer to this question pertains to everything from a patients decision to use a GLP-1 medication or a providers likelihood of prescribing one, to health plans and employers coverage decisions, and investment strategies for companies ranging from consumer products to pharma
You need to seek urgent help
Think of it this way: the GHRH (like CJC-1295) presses the accelerator on GH production, while the GHRP (Ipamorelin) takes the brakes off